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Toxicogenomic studies are increasingly used to uncover potential
biomarkers of adverse health events, enrich chemical risk
assessment, and to facilitate proper identification and treatment
of persons susceptible to toxicity. Current approaches to biomarker
discovery through gene expression profiling usually utilize a single
or few strains of rodents, limiting the ability to detect biomarkers
that may represent the wide range of toxicity responses typically
observed in genetically heterogeneous human populations. To
enhance the utility of animal models to detect response biomarkers
for genetically diverse populations, we used a laboratory mouse
strain diversity panel. Specifically, mice from 36 inbred strains
derived fromMus mus musculus,Mus mus castaneous, andMus mus
domesticus origins were treated with a model hepatotoxic agent,
acetaminophen (300 mg/kg, ig). Gene expression profiling was
performed on liver tissue collected at 24 h after dosing. We
identified 26 population-wide biomarkers of response to acetamin-
ophen hepatotoxicity in which the changes in gene expression
were significant across treatment and liver necrosis score but not
significant for individual mouse strains. Importantly, most of these
biomarker genes are part of the intracellular signaling involved in
hepatocyte death and include genes previously associated with
acetaminophen-induced hepatotoxicity, such as cyclin-dependent
kinase inhibitor 1A (p21) and interleukin 6 signal transducer
(Il6st), and genes not previously associated with acetaminophen,
such as oncostatin M receptor (Osmr) and MLX interacting
protein like (Mlxipl). Our data demonstrate that a multistrain
approach may provide utility for understanding genotype-
independent toxicity responses and facilitate identification of
novel targets of therapeutic intervention.
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Biological monitoring to assess potential toxicity of chemical
and pharmaceutical compounds relies heavily on the availability
of sensitive, specific, and widely applicable biomarkers of toxic
effects (International Programme on Chemical Safety, 1993).
Toxicogenomics has been used at all stages of chemical risk
assessment, and it is thought that gene expression changes may
be utilized as biomarkers of adverse effects (Casciano and
Woodcock, 2006). Current approaches often attempt to classify
compounds with the goals of predicting adverse responses to
specific chemical classes (Fostel, 2007), understanding the
underlying biological mechanism of toxicity (Dix et al., 2006),
or identifying key nodes in the toxicity pathway that may serve
as effect biomarkers (Fry et al., 2007). Extensive proprietary
(Castle et al., 2002; Ganter et al., 2008) and public (Mattingly
et al., 2006; Waters et al., 2008) databases containing gene
expression profiles and pathological end points derived from
rodent and human tissues exposed to a variety of chemicals have
been developed, thereby allowing the scientific community to
mine the data for toxicity biomarkers of interest.
Many biomarkers of toxicity may be surrogate measures for
the genetics of an individual, which can play a major role in
determining the threshold of toxicity of a given compound
(Lanfear and McLeod, 2007). Compelling research has led to
the identification of gene variants that correlate with drug
toxicity (Feero et al., 2008), and recent pharmacogenomic
research efforts have made significant advances in connecting
variability in responses to drug efficacy and/or toxicity to
genetic polymorphisms (Weiss et al., 2008). While major
research efforts are seeking genetic and genomic markers that
could identify individuals susceptible to toxicity, less attention
is given to the fact that interindividual variability in responses
and genetic control of gene expression may present a challenge
for finding robust population-wide expression biomarkers of
toxicity responses (Gatti et al., 2007). Indeed, while toxicoge-
nomics has been used widely for the study of toxicity
biomarkers across compounds and across species, its useful-
ness in determining biomarkers that are relatable to a diagnostic
toxicity within a genetically diverse human population is
limited by a lack of intraspecies comparisons.
To address the need for a biomarker identification strategy
that is independent of population heterogeneity, we utilized
a mouse Laboratory Strain Diversity Panel (Bogue and Grubb,
2004). The use of a genetically defined panel of mice has
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advantages over classical toxicology testing strategies that
utilize a single inbred or outbred strain because it takes
advantage of the vast genetic diversity that is available among
inbred mouse lines (Roberts et al., 2007). We hypothesized that
toxicity responses across a panel of strains will produce a range
of effects expected in a human population and that this
phenotypic diversity can be used to identify population-
dependent and -independent mRNA transcript biomarkers of
response. To test this hypothesis, we selected the model
hepatotoxic agent, acetaminophen. We observed a dramatic
gradient of acute hepatotoxicity across strains, and the analysis
of liver gene expression data revealed 26 genes that correlated
with liver necrosis outcome and were not affected by genetic
differences between individual strains. Thus, these genes, the
majority of which are tightly linked in a cell death and
proliferation network, can serve as response biomarkers for
acetaminophen-induced toxicity responses across a genetically
heterogeneous population.
MATERIALS AND METHODS
Mice. Male mice (aged 7–9 weeks) were obtained from the Jackson
Laboratory (Bar Harbor, ME) and housed in polycarbonate cages on Sani-
Chips irradiated hardwood bedding (P. J. Murphy Forest Products Corp.,
Montville, NJ). Animals were fed NTP-2000 wafer diet (Zeigler Brothers, Inc.,
Gardners, PA) and water ad libitum and maintained on a 12-h light-dark cycle.
Mice utilized in this study comprise 36 inbred strains that are priority strains for
the Mouse Phenome Project (Bogue and Grubb, 2004): 129S1/SvImJ, A/J,
AKR/J, BALB/cByJ, BTBR Tþ tf/J, BUB/BnJ, C3H/HeJ, C57BL/10J,
C57BL/6J, C57BLKS/J, C57BR/CdJ, C57L/J, CAST/EiJ, CBA/J, CZECHII/
EiJ, DBA/2J, FVB/NJ, JF1/Ms, KK/HlJ, LP/J, MA/MyJ, MSM/Ms, NOD/
ShiLtJ (formerly NOD/LtJ), NON/LtJ, NZO/H1LtJ, NZW/LacJ, P/J, PERA/
EiJ, PL/J, PWD/PhJ, RIIIS/J, SEA/GnJ, SJL/J, SM/J, SWR/J, and WSB/EiJ. F1
hybrid mice, B6C3F1/J, were also used for phenotypic measurements. These
studies were conducted under a protocol approved by the Institutional Animal
Care and Use Committee at the University of North Carolina at Chapel Hill.
Acetaminophen administration and sample collection from mice. Mice
were singly housed and fasted 18 h prior to intragastric dosing with
acetaminophen (99% pure; Sigma-Aldrich, St Louis, MO; N ¼ 3–4 per strain)
or vehicle (0.5% methyl 2-hydroxyethyl cellulose; Sigma-Aldrich; N ¼ 2 per
strain, except for strains PERA/EiJ, SWR/J, and CZECHII/EiJ (N ¼ 3), as well
as strains AKR/J and CAST/EiJ (N ¼ 1, i.e., sufficient tissue was not available).
The dose of 300 mg/kg was delivered in 10 ml/kg of vehicle. Dosing was
performed at the same time of day (9:00 A.M.) throughout the study as diurnal
effects have been shown to affect gene expression in rodent studies (Boorman
et al., 2005). Feed was returned 3 h after dosing; animals were necropsied 24 h
after treatment (nembutal 100 mg/kg, ip; Abbott Laboratories, Chicago, IL).
Livers were quickly excised following exsanguination, and sections of the left
lateral lobe were placed in 10% phosphate-buffered formalin for immunohis-
tochemical analyses. Tissues were stored in formalin solution for 72 h prior to
transferring tissue to 70% ethanol. Formalin-fixed liver tissue was then
embedded in paraffin. Remaining liver from the left lobe was snap frozen in
liquid nitrogen and stored at  80C for RNA extraction.
Liver histopathology. Paraffin-embedded liver tissue was cut to 5-lm
sections in duplicate and stained with hematoxylin and eosin. Liver injury in the left
liver lobe was blindly scored by A.H.H. and confirmed by a certified veterinary
pathologist. Necrosis was quantified by unbiased stereology using a point-counting
technique (Mouton, 2002). Briefly, a grid with 100 evenly spaced points was
overlaid on printed images of liver sections taken at3100 magnification. The total
number of points lying in an area of necrosis was divided by the total number of
points lying completely within the entire tissue section to determine a percent
necrosis score (0–100%). The necrosis score for each animal in the study is publicly
available from the Mouse Phenome Database (http://phenome.jax.org/pub-cgi/
phenome/mpdcgi?rtn ¼ projects/details&sym ¼ Threadgill1).
RNA isolation. To eliminate variability in transcript expression that might
arise between liver lobes, the left liver lobe was selected for the remainder of
the data analysis and gene expression profiling. RNA was extracted from the 30
mg of tissue derived from the left lobe of sample livers using the Qiagen
RNeasy kit (Qiagen, Valencia, CA). RNA concentrations were measured using
a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE), and quality was verified using the Agilent Bio-Analyzer (Agilent
Technologies, Santa Clara, CA). RNA was determined to be of good quality for
use in microarray hybridizations if the 28S:16S rRNA ratio was greater than 1.8
and the 260/280 nm absorbance ratio was in the range of 1.9–2.1.
Microarray hybridizations. In this study, all RNA samples were hybridized
to arrays individually; none were pooled. RNA amplifications and labeling were
performed using Low RNA Input Linear Amplification kits (Agilent Technol-
ogies). For hybridization, 750 ng of total RNA from each mouse liver was
amplified and labeled with fluorescent dye (Cy5). In parallel, 750 ng of
a common reference RNA (Icoria, Inc., RTP, NC) was labeled with the
fluorescent dye, Cy3, in order to standardize analysis of global gene expression
between mouse strains (Bammler et al., 2005). Labeled cRNA was then
processed and hybridized to Agilent Mouse Toxicology Arrays (catalog# 4121A,
22,575 features) according to the manufacturer’s protocol. Details regarding the
microarray probe set on the 4121A array are available via the Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc ¼ GPL891). Fol-
lowing hybridization, arrays were washed using a custom protocol developed by
Icoria, Inc. Briefly, array gaskets were removed under immersion in wash
solution 1 (63 sodium chloride/sodium phosphate/EDTA [SSPE], 0.005%
N-lauroylsarcosine). Arrays were washed with wash solution 1 and incubated for
1 min with gentle agitation on a magnetic stir plate. A second incubation was
performed in wash solution 2 (0.063 SSPE, 0.005% N-lauroylsarcosine).
Data analysis of significantly changed transcripts. Raw microarray
intensity values were obtained from Agilent Feature Extraction software (v8.5)
and archived in the UNC Microarray Database (http://genome.unc.edu). Raw
data are available to the public through this database. The log2 ratio of Cy5/Cy3
intensity was normalized using locally weighted scatterplot smoothing to
eliminate intensity bias of features. Transcripts with fewer than 70% available
data across samples were excluded from the analysis, reducing the probe list to
15,509 transcript probes. Available data are defined as those probes that are
neither saturated nor below the limit of quantification. Intensity ratios were
transformed to eliminate hybridization batch effects using the batch normaliza-
tion feature in Partek Genomics Suite (Partek, Inc., St Louis, MO). Analysis of
significant transcripts was performed using an analysis of covariance
(ANCOVA) model in Partek in which the main effects were mouse strain,
treatment, the interaction of mouse strain and treatment, and the sample necrosis
score. Transcripts were called significantly different if the p value was less than
a threshold determined by a step-down false discovery rate (FDR, Benjamini and
Liu, 1999) (a ¼ 0.01) to correct for multiple comparisons across array features.
Heat maps were generated using hierarchical agglomerative clustering.
Single-nucleotide polymorphisms in probe sequences. There is the
potential that strain-specific gene expression differences found using microarrays
could be produced by single-nucleotide polymorphisms (SNPs) that occur within
probe sequences (Alberts et al., 2007). The genomic locations of the probes on
the Agilent G4121A microarray were obtained from Agilent Technologies. High-
density mouse SNP data containing 7.87 3 106 SNPs were obtained from
Szatkiewicz et al. (2008) for the 36 inbred strains used in this study. We found
that 4,091 of the 20,868 probes on the Agilent 4121A array contained at least one
SNP. For each probe that contained an SNP, we performed Student’s t-tests
between the C57BL/6J allele-containing strains and those with the opposite
allele. Of these, 948 probes contained an SNP for a single strain, providing no
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meaningful way to carry out a t-test. We performed Fisher’s exact test on the
remaining 3,143 probes to determine if there were more probes with C57BL/6J
allele high expression on the list of significant probes than would be expected by
chance. We found a significant effect of probe SNPs within the data set (P ¼
0.01) and identified 49 probes that were significantly affected at a 5% FDR.
We removed these probes from further analysis.
Functional analysis of significant genes. Ingenuity Pathway Analysis
(IPA, IPA v. 7.1; Ingenuity Systems, Redwood City, CA) was used to
determine canonical pathways that are enriched by the significant transcripts
identified by the ANCOVA model for each factor. Significance values were
calculated based upon a right-tailed Fisher’s exact test that determines whether
a pathway is overrepresented by calculating whether the genes in a given
pathway are enriched within the data set compared to all genes on the array in
the same pathway; p < 0.05 was selected as the cutoff for significance based on
IPA threshold recommendations. Only those pathways with a p value above the
threshold and having more than two representative genes in the data set were
considered significant. The gene network of the 26 response biomarkers was
prepared by determining connecting nodes, interactions, and cellular compart-
ments using the IPA software.
RESULTS
Histopathology of Liver Toxicity across Inbred Mouse Strains
At 24 h after dosing with 300 mg/kg of acetaminophen (ig),
we observed centrilobular necrosis in the liver consistent with
that previously reported for acute doses of acetaminophen
(Hinson et al., 2004; James et al., 2003). Necrosis was
accompanied by minor inflammatory infiltration into the
hepatic parenchyma, and in varying degrees, hemorrhage was
also present. Quantitative liver necrosis scores reflective of the
proportion of the affected area were obtained from the left liver
lobe (Foley et al., 2006) and demonstrated a wide range of
toxicity across the panel of inbred mouse lines (Fig. 1). The
rank order of sensitivity to acetaminophen-induced liver injury
across strains shows that the majority of tested strains (30/36)
sustained less than 40% liver necrosis, while 6 strains sustained
liver necrosis of between 40 and 100%.
Determination of Gene Transcripts Associated with Strain,
Treatment, and Liver Necrosis
Gene expression values were collected on individual animals
in this study (vehicle and acetaminophen-treated mice) and used
for principal components analysis to visually examine the
patterns in global mRNA transcript differences (Fig. 2). The
unsupervised analysis displayed separation of the samples by
both treatment and by the amount of liver necrosis sustained in
the animal, indicating that gene signatures may be determined
that are correlative with liver toxicity due to acetaminophen.
To determine those transcripts in which expression was
significantly differentiated among the experimental factors, an
ANCOVA model was used. Covariate factors for each
individual mouse included the strain (genotype), treatment
(vehicle or acetaminophen), the interaction between strain and
treatment because of anticipated genotype-specific effects on
acetaminophen metabolism and transport, and the liver necrosis
score. The number of transcripts significantly changed among
each experimental factor is depicted in a Venn diagram
(Fig. 3A). Interestingly, the majority of genes (1,511) found to
be significantly different between samples in the ANCOVA
analysis were attributed to the strain effect, not acetaminophen
treatment, or the degree of liver necrosis. These genes were
found not to have a significant effect of probe SNPs within the
data set (see ‘‘Materials and Methods’’ section). This strain-
specific gene set best represents those genes that differ in basal
levels among the panel of inbred mouse strains and whose
expression is likely to be influenced by genetic polymorphisms
(Gatti et al., 2007). Similarly, those genes that were significant
for all three factors (strain, treatment, and necrosis) best
represent the genes that could yield important information on
the mechanism of acetaminophen toxicity but would make
a poor biomarker because basal levels are affected by
individual genotype.
FIG. 1. Liver necrosis measured across strains after acetaminophen
treatment shows a gradient of response across mouse strains at 24 h.
FIG. 2. Principal components analysis. PCA of the global gene expression
changes in the left liver lobe following treatment with vehicle (0.5% methyl
cellulose) or acetaminophen (300 mg/kg, ig, 24 h). Acetaminophen-treated
samples are depicted as triangles and vehicle-treated samples are depicted as
squares. The data separate along the first principal component (PC1) by
treatment. There is additional separation of gene expression along PC1 and PC2
by the amount of liver necrosis sustained (white to black scale bar ¼ 0–100%
necrosis).
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Next, functional pathway analysis was performed in order to
determine biological pathways most affected by the main ex-
perimental factors of strain, treatment, or liver injury (Table 1).
Several pathways were identified as significant within the
necrosis-specific gene set. As expected, those pathways that were
most significantly enriched are associated with cellular growth
processes, including signaling mediated by interleukin (IL)-10,
IL-6, extracellular signal-regulated kinase (ERK)/mitogen acti-
vated protein kinase (MAPK), and nuclear factor kappa (NF- jB).
Interestingly, a diversity of canonical pathways was
enriched within the gene set that was significant for a main
effect of strain alone. These pathways include genes involved
in mitochondrial dysfunction as well as metabolic pathways.
Interestingly, the pathway for lipopolysaccharide (LPS)/IL-1–
mediated inhibition of retinoid X receptor (RXR) function
was significantly enriched and included critical mediators
such as peroxisome proliferator–activated receptor alpha and
tumor necrosis factor. Taken together, the large number of
genes and canonical pathways that are affected by strain-
dependent gene expression indicate that choice of rodent
strain in toxicity risk assessment is of importance.
Population-Based Gene Expression Biomarkers of Response
There were 26 transcripts whose expression was affected
significantly by both treatment and by the toxicity outcome
(i.e., liver necrosis), but not the subject’s genotype (Table 2).
We reason that these genes could serve as population-based
biomarkers of response. To visualize gene expression changes
of the biomarker transcripts across individuals, a heat map was
generated (Fig. 3B). A clear gradient of expression changes can
be observed for each of these genes depending on the amount
of necrosis sustained by an individual mouse. Expression of 17
of these transcripts increased, while 9 genes decreased as liver
necrosis increased in acetaminophen-treated mice.
In order to determine whether molecular interactions exist
among the population-based transcript biomarkers, a pathway
map was constructed using IPA. This analysis revealed that 16
of the 26 population-based response biomarkers are closely
linked in a cell death and proliferation network centered on cell
cycle regulating genes Trp53, Myc, Jun, and Cdkn1a (p21)
(Fig. 4). Closely associated with this network were the
cytokine-responsive genes interleukin 6 signal transducer
(Il6st) and oncostatin M receptor (Osmr) (Figs. 3C and 3D),
as well as the glucose-responsive transcription factor MLX
interacting protein like (Mlxipl) and CDC14 cell division cycle
14 homolog B (Cdc14b) (Figs. 3E and 3F).FIG. 3. Detection of population-based biomarkers of response from gene
expression data. (A) The Venn diagram depicts the number of genes
significant for each factor in the ANCOVA model, namely treatment, strain
(genotype), and the individual’s liver necrosis score at 24 h. Population-based
biomarkers of response are those 26 genes that are significant for treatment
and necrosis score, but not by genotype. (B) The expression patterns of the 26
biomarkers are depicted in a heat map in which samples (rows) were ordered
first by necrosis score and then by treatment. Unsupervised hierarchical
clustering was performed on the genes (columns). Biomarker gene expression
for each sample as plotted against the liver necrosis score is shown for
transcript expression that is increased with necrosis: the oncostatin M receptor
subunits Il6st (C) and Osmr (D) and for transcript expression that is decreased
with necrosis: Mlxipl (E) and Cdc14b (F). Values for vehicle-treated mice are
shown in open squares and values for APAP-treated mice are shown in closed
circles. The linear regression trend lines for acetaminophen-treated samples
are shown.
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DISCUSSION
Identification of the Population-Based Biomarkers of Toxicity
Response
Decades of mechanistic investigations into the liver toxicity
of acetaminophen have concluded that (1) metabolic activation
to the reactive metabolite N-acetyl-p-benzoquinone imine and
its binding to cellular proteins is an essential initiating event for
the toxicity, (2) intracellular events involved in cell death such
as mitochondrial dysfunction and formation of reactive oxygen
and nitrogen species propagate the injury, and (iii) inflamma-
tory response to cell death in the liver may exacerbate the
damage (Jaeschke and Bajt, 2006; Kaplowitz, 2005). Thus, the
fact that our study not only identified 26 biomarker genes in
which expression across strains was associated with the level of
liver necrosis but also showed that 16 of the 26 response
biomarker genes are involved in cell death pathways and form
a closely linked molecular network confirms a central role for
intracellular cell signaling in acetaminophen-induced liver
toxicity.
Not only are cell death–related genes mechanistic biomarkers
of response across genetically diverse individuals as identified in
our work, they also have been shown to be consistently affected
and significantly correlated with the acetaminophen-induced
liver toxicity phenotype in a multicenter toxicogenomic study
(Beyer et al., 2007). The study, conducted at seven different
laboratories around the United States, used only one inbred
strain, C57BL/6J; however, it showed that Myc is induced by
acetaminophen and that a myelocytomatosis oncogene-centered
cell death pathway is the most significant network of proteins
associated with liver injury in the mouse at 6, 12, and 24 h after
treatment with a dose identical to that used in our work.
Furthermore, expression of cyclin-dependent kinase inhibitor
p21 (Cdkn1a), a central gene in the biomarker gene network, has
been shown previously to be required for liver necrosis in
rodents (Kwon et al., 2003). In addition, decreased levels of
Cdc14b are consistent with increased activation of Trp53 (Kwon
et al., 2003), which may be a compensatory mechanism to signal
for an increase in cellular repair following acetaminophen
overdose. Collectively, 16 of the 26 response biomarker genes
identified in our study may be mechanism-relevant biomarkers
of liver necrosis that have potential to be used to profile toxicity
across individuals and in multiple independent microarray
studies.
Importantly, the genes identified in this study are interesting
not only as potential biomarkers but also as mediators of
acetaminophen-induced cell death and regeneration in liver.
For example, the role of OSMR in acetaminophen-induced
liver injury deserves attention because genes coding for its two
subunits, Osmr and Il6st, were both identified as genotype-
independent biomarkers of the liver toxicity outcome. It is
known that Il6st expression is essential for the control of the
hepatic acute-phase response during liver regeneration (Streetz
et al., 2003; Wuestefeld et al., 2003). However, while IL-6
represents one of the best-studied cytokines, there is relatively
little known about the biological activities of oncostatin M
(OSM), a cytokine secreted by activated T lymphocytes,
macrophages, and neutrophils. OSM may have a profibrotic
role in liver injury owing to its ability to induce tissue inhibitor
of metalloproteinase (TIMP) 1 (Richards et al., 1993) and
TIMP3 (Li and Zafarullah, 1998). While OSM has been shown
to be increased following acetaminophen-induced liver injury
(Masubuchi et al., 2003), Osmr transcript levels have not been
shown previously to correlate with liver necrosis end points.
Additionally, knockout mice deficient for Osmr display defects
in liver regeneration following carbon tetrachloride exposure
(Nakamura et al., 2004); more importantly, administration of
exogenous OSM ameliorated liver injury in wild-type mice
(Nakamura et al., 2004).
In addition, expression of Mlxipl, also known as carbohydrate
response element–binding protein (Chrebp), a transcription factor
that plays a central role in the dietary regulation of hepatic gene
TABLE 1
Enriched Ingenuity Canonical Pathways Listed by Experimental
Factor








Necrosis IL-10 signaling 6 71 8.42 3 105
IL-6 signaling 5 96 4.73 3 103
Glycine, serine, and threonine
metabolism
4 144 5.61 3 103
ERK/MAPK signaling 6 192 1.92 3 102
NF-jB signaling 5 147 2.35 3 102
Propranolate metabolism 4 126 3.29 3 102
Clathrin-mediated endocytosis 5 167 3.31 3 102
Starch and sucrose metabolism 3 191 3.31 3 102
Macropinocytosis 3 72 4.47 3 102
LXR/PXR activation 3 85 4.66 3 102
Strain Mitochondrial dysfunction 14 170 5.96 3 104
Pentose phosphate pathway 6 88 6.5 3 103
Purine metabolism 23 417 9.75 3 103
Pyrimidine metabolism 15 228 1.19 3 102
Death receptor signaling 7 65 1.5 3 102
Inositol phosphate metabolism 12 172 1.71 3 102
Propranolate metabolism 8 126 1.83 3 102
Nicotinate and nicotinamide
metabolism
10 129 2.38 3 102
LPS/IL-1–mediated inhibition
of RXR function
14 197 3.05 3 102
Interferon signaling 5 29 3.06 3 102
Cell cycle: G1/S checkpoint
regulation
6 58 3.58 3 102
Role of PXR in interferon
induction and antiviral response
5 47 4.95 3 102
Treatment TREM1 signaling 3 69 5.31 3 104
Endothelin-1 signaling 3 183 1.02 3 102
Glucocorticoid receptor signaling 3 278 2.57 3 102
Note. LXR, liver X receptor; PXR, pregnane X receptor; RXR, retinoid X
receptor; TREM1, triggering receptor expressed on myeloid cells 1.
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expression by glucose, was decreased as the degree of liver
necrosis increased in animals treated with acetaminophen. Several
recent studies demonstrated that acetaminophen can affect blood
glucose levels (Kendig et al., 2008) and improve glucose tolerance
in mice fed a high-fat diet (Shertzer et al., 2008). The former study
showed that daily administration of acetaminophen prevented
approximately 70% of weight gain compared to mice fed the high-
fat diet alone, even at a daily dose that was lower than half of the
maximum recommended weight-adjusted human dose (Kendig
et al., 2008). In addition, decreases in liver glucose and increases in
lipid content were observed in the mouse liver after acetamino-
phen overdose using nuclear magnetic resonance-based metab-
olomics (Coen et al., 2004) and may explain the dramatic decrease
in Mlxipl transcript levels observed in our work. While further
studies need to be conducted to link effects on glucose modulation
at subacute doses of acetaminophen with the acute toxic doses
used in our study, changes in Mlxipl expression may yield insight
into the mechanism of these phenomena.
An important limitation of the animal studies of toxicity
mechanisms is the ability to translate the data to clinical
TABLE 2
Population-Based Biomarker Transcripts Detected by Analysis of Covariance that Have a Main Effect of Treatment and Necrosis
Score, but Not of Strain
Gene symbol Gene name Necrosis p valuea Treatment p valuea Strain p valuea R2
Decreased
C14ORF122 Chromosome 14 open-reading frame 122 7.9 3 1010 3.7 3 1007 1.1 3 102 0.58
Tlcd1 TLC domain containing 1 1.3 3 1009 2.4 3 1007 5.4 3 104 0.62
KIAA1370 KIAA1370 2.9 3 1009 8.1 3 1008 8.6 3 104 0.54
Rhbg Rhesus blood group–associated B
glycoprotein
4.3 3 1009 5.3 3 1007 2.2 3 103 0.54
Cdc14b CDC14 cell division cycle 14 homolog B
(Saccharomyces cerevisiae)
1.9 3 1008 1.1 3 1007 2.5 3 103 0.59
Lgr5 Leucine-rich repeat containing G protein–
coupled receptor 5
2.6 3 1008 1.6 3 1007 2.7 3 103 0.55
L2hgdh L-2-hydroxyglutarate dehydrogenase 3.0 3 1007 2.1 3 1007 6.4 3 103 0.55
Mcm10 Minichromosome maintenance deficient 10
(Saccharomyces cerevisiae)
3.3 3 1007 2.5 3 1007 8.2 3 105 0.40
Mlxipl Carbohydrate response element–binding
protein, MLX interacting protein like
5.9 3 1007 4.1 3 1007 2.9 3 102 0.53
Increased
Col4a1 Procollagen, type IV, alpha 1 1.1 3 1013 1.1 3 1008 9.8 3 107 0.68
Tmem2 Transmembrane protein 2 4.8 3 1012 1.1 3 1008 9.7 3 107 0.59
Slc39a6 Solute carrier family 39 (metal ion
transporter), member 6
4.5 3 1011 2.4 3 1007 1.8 3 105 0.58
Serpine1 Serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1),
member 1
1.3 3 1009 4.3 3 1007 1.8 3 105 0.63
Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) 1.4 3 1009 7.5 3 1012 5.6 3 102 0.59
D10Ertd438e DNA segment, chromosome 10, ERATO
Doi 438, expressed
4.2 3 1009 2.0 3 1009 9.9 3 103 0.60
Psme3 Proteaseome (prosome, macropain) 28
subunit, 3
5.5 3 1008 5.7 3 1007 1.2 3 101 0.55
Ddx39 DEAD (Asp-Glu-Ala-Asp) box
polypeptide 39
6.9 3 1008 2.8 3 1008 3.1 3 104 0.51
SKIL SKI-like oncogene 6.9 3 1008 8.2 3 1009 2.5 3 101 0.56
Map3k6 Mitogen-activated protein kinase kinase
kinase 6
7.7 3 1008 4.6 3 1007 2.5 3 103 0.52
Pex1 Peroxisome biogenesis factor 1 8.4 3 1008 1.7 3 1009 1.1 3 102 0.56
Il6st Interleukin 6 signal transducer 2.0 3 1007 4.3 3 1008 1.6 3 101 0.41
Osmr Oncostatin M receptor 2.1 3 1007 2.1 3 1007 1.8 3 101 0.56
Csf2rb2 Colony-stimulating factor 2 receptor, beta 2,
low-affinity (granulocyte-macrophage)
3.3 3 1007 1.2 3 1010 7.9 3 104 0.51
Cd68 CD68 antigen 4.2 3 1007 3.2 3 1012 1.7 3 102 0.53
2010109K11Rik RIKEN cDNA 2010109K11 gene 4.5 3 1007 4.4 3 1007 2.1 3 101 0.56
Ipo4 Importin 4 6.4 3 1007 2.9 3 1007 5.5 3 103 0.52
aPvalue thresholds were calculated by determining the 1% FDR. These thresholds were necrosis, p6.83107; treatment,p6.53107; and strainp83107.
None of these genes has a significant strain 3 treatment interaction effect.
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findings. A recent study that compared acetaminophen toxicity
in the rat and humans showed that, in the rat, gene expression
data from peripheral blood cells can provide valuable in-
formation about overtly toxic exposure levels (Bushel et al.,
2007). Furthermore, based on the subset of 66 genes that were
retrieved from a rat blood training set, it was possible to
distinguish humans who overdosed on acetaminophen (five
cases) from normal individuals (three controls). None of the
FIG. 4. Biomarker gene network. Network analysis of the 26 biomarkers of response using IPA revealed that 16 of the biomarkers are closely associated with
molecular pathways involved in cell death and proliferation. The network is shown here with protein products localized to their endogenous subcellular
compartments (nucleus, cytoplasm, cell membrane, and extracellular space). Transcripts that are increased or decreased as necrosis increased are colored blue and
yellow, respectively.
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26 genes identified in our multistrain study could be matched
to human blood transcriptome and serum alanine aminotrans-
ferase data from subjects overdosing on acetaminophen
reported by Bushel et al. (2007). However, it should be
noted that the small sample size of the human data set, as well
as the unavoidable variability in the timing of the collection of
human blood samples (2 or 5 days after ingestion of
acetaminophen), could have been the major factors for lack
of mouse-to-human overlap.
The use of toxicogenomics as a tool in toxicology calls for
the careful evaluation of study designs. Because one of the
major applications of toxicogenomics is to discover biomarkers
of toxicity that are relevant to humans, great care must be taken
in choosing the appropriate model systems. Traditional risk
assessment practices using animal models allow for the control
of many experimental factors except for genetics. Although
rodent models have been widely used for toxicity testing, their
utility is often limited by (1) inaccurate generalizations from
a single genome, (2) inability to distinguish small and
biologically important changes from background variation,
(3) ineffective exploitation of reproducible genetic variation to
dissect differential response to chemical exposure, and (4)
inefficient use of defined genetic backgrounds to model
particular phenotypic profiles observed in human populations.
To address these important limitations, panels of genetically
defined organisms, such as inbred mouse lines, that provide
a fixed genotype within a particular strain but encompass great
genetic diversity across strains are being used more frequently
in biomedical research (Festing, 2001). Genetic variation
among individuals is reflected in variations in gene expression
levels (Schadt et al., 2003), which introduces additional
challenges into toxicology research. Inbred mouse strains are
reasonably well suited for identifying whole-genome response
signatures indicative of chemical exposure because much is
known regarding genetic lineage and derivation for hundreds of
strains, and the number and distribution of genetic poly-
morphisms among mouse strains is equal to or exceeds that in
the human population (Roberts et al., 2007). This approach has
the added advantage of ‘‘repeat testing’’ in genetically identical
individuals within a given strain, yielding important informa-
tion regarding reproducibility of the response.
The largest group of genes identified in this study as
significantly different between individuals comprised tran-
scripts that differ in basal levels between inbred mouse strains,
despite the fact that over two thirds of all strains exhibited
variable degrees of liver damage. We also observed a high
degree of intrastrain variability in toxicity that has been
reported by other investigators, particularly for the C57BL/6J
mouse (Beyer et al., 2007) and the Sprague-Dawley rat
(Clayton et al., 2006). This variability can be due to a variety of
factors that often cannot be controlled by the experimenter in
standard toxicity studies, including epigenetic effects and
differential contributions of intestinal microflora. In summary,
our data underscore the value of multistrain experiments that
can avert the risk of large genotype effects in a particular strain
of animals used for toxicity risk assessment to determine
biomarkers of response.
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